| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967232 | Vaccine | 2013 | 7 Pages |
Abstract
⺠The burden of disease attributable to CMV is high. ⺠CMV has been assumed to be a formidable target for vaccinologists. ⺠Laboratory measures of CMV infection have been defined as candidate endpoints for vaccine trials. ⺠Three recent randomised controlled trials have reported encouraging results. ⺠CMV may become a vaccine preventable infection.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Paul Griffiths, Stanley Plotkin, Edward Mocarski, Robert Pass, Mark Schleiss, Philip Krause, Stephanie Bialek,